Table 3.
Analysis of potential predictors for developing skin complaints within 4 weeks after treatment for painful spinal metastases
| Baseline variables | % of patients with | Odds ratio (95% CI) | |
|---|---|---|---|
| Skin complaints | UVAa | MVAa | |
| Primary tumor | |||
| Breast cancer | 31% | 1.00 | 1.00 |
| Prostate cancer | 28% | 0.87 (0.47–1.61) | 0.95 (0.50–1.79) |
| Lung cancer | 49% | 2.19 (1.17–4.11) | 2.27 (1.20–4.30) |
| Other | 36% | 1.26 (0.61–2.62) | 1.28 (0.61–2.70) |
| Age | |||
| ≤ 65 years | 39% | 1.00 | # |
| > 65 years | 30% | 0.66 (0.41–1.06) | |
| Gender | |||
| Male | 35% | 1.00 | # |
| Female | 33% | 0.92 (0.58–1.47) | |
| KPS | |||
| 90–100 | 34% | 1.00 | # |
| 70–80 | 31% | 0.84 (0.46–1.56) | |
| 20–60 | 40% | 1.29 (0.66–2.51) | |
| Pain score | |||
| 2–4 | 29% | 1.00 | # |
| 5–7 | 34% | 1.22 (0.65–2.31) | |
| 8–10 | 38% | 1.48 (0.76–2.90) | |
| Visceral metastases | |||
| No | 33% | 1.00 | # |
| Yes | 38% | 1.27 (0.76–2.14) | |
| Systemic therapy | |||
| No | 38% | 1.00 | # |
| Yes | 31% | 0.75 (0.47–1.20) | |
| Treatment schedule | |||
| 6 × 4 Gy | 31% | 1.00 | # |
| 1 × 8 Gy | 37% | 1.34 (0.84–2.15) | |
| Pain medication | |||
| No opioids | 33% | 1.00 | # |
| Opioids | 35% | 1.09 (0.68–1.75) | |
| Spinal localization | |||
| Thoracic spine | 42% | 1.00 | 1.00 |
| Thoraco-lumbar spine | 39% | 0.91 (0.39–2.14) | 0.95 (0.40–2.25) |
| Lumbar spine | 27% | 0.52 (0.31–0.88) | 0.54 (0.32–0.91) |
| Lumbo-sacral spine | 55% | 1.69 (0.49–5.89) | 1.83 (0.52–6.49) |
| Treatment technique | |||
| PA | 33% | 1.00 | # |
| APPA | 37% | 1.19 (0.70–2.02) | |
95%, CI 95% confidence interval; UV, A univariate analysis; MVA, Multivariable analysis; KPS, Karnofsky performance status; PA, Posterior-anterior field; APPA, Anterior-posterior and posterior-anterior field
aLogistic regression analysis
#Did not remain in the final model